SUMSearch 2

Original studies

Systematic reviews

Guidelines

 
112 possible original studies PubMed found after 3 searches. The first 50 citations are:
1. Effect of single-administration of D-sorbitol pretreatment on the bitterness and continued willingness to take asenapine: a randomized, single-blind, placebo-controlled, crossover trial.
BMC Psychiatry 2024;24:1. PMID: 38291403 , PubMed Central, doi: 10.1186/s12888-024-05549-x, Cited by. Cite
Conclusion: Our findings indicate that single-administration of D-sorbitol significantly reduces the bitterness of asenapine. In countries where flavored asenapine is not available, this finding could benefit patients who were not accustomed to its bitter taste.
2. Optimal dose for the efficacy of asenapine in patients with schizophrenia: Real-world data.
Neuropsychopharmacol Rep 2024;44:1. PMID: 37926930 , PubMed Central, doi: 10.1002/npr2.12389, Cited by. Cite
Conclusion: These results suggest that asenapine doses >10 mg/day may be more effective than 10 mg/day in the treatment of schizophrenia; however, further studies are needed to confirm these findings.
3. Umbrella Review: Association Between Antipsychotic Drugs and Metabolic Syndrome Hallmarks in Children and Adolescents.
J Am Acad Child Adolesc Psychiatry 2024;63:3. PMID: 37391174 , doi: 10.1016/j.jaac.2023.04.018, Cited by. Cite
Conclusion: By collating meta-analyses assessing biochemical markers of metabolic syndrome in antipsychotic-treated children, we conclude that olanzapine should not be the antipsychotic of choice in patients at risk for hypertriglyceridemia or hypercholesterolemia. Aripiprazole and lurasidone appear to be better tolerated in terms of metabolic adverse events. Insufficient meta-analytic data are available to provide a precise risk estimate of metabolic syndrome, and, overall, the quality of evidence is low.
4. Long-term safety and efficacy of sublingual asenapine for the treatment of schizophrenia: A phase III extension study with follow-up for 52 weeks (P06125)-Secondary publication.
Neuropsychopharmacol Rep 2023;43:3. PMID: 37232002 , PubMed Central, doi: 10.1002/npr2.12342, Cited by. Cite
Conclusion: The sustained efficacy rate, as evaluated by the Positive and Negative Syndrome Scale total score and other measures, remained at approximately 50% between 6 and 12 months of treatment. These results suggest that long-term treatment with asenapine is well tolerated and provides sustained efficacy.
5. Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis.
World Psychiatry 2023;22:2. PMID: 37159349 , PubMed Central, doi: 10.1002/wps.21089, Cited by. Cite
Conclusion: Concerning weight gain, the impact of olanzapine was higher than all other antipsychotics, with a mean difference ranging from -4.58 kg (95% CI: -5.33 to -3.83) compared to ziprasidone to -2.30 kg (95% CI: -3.35 to -1.25) compared to amisulpride. Our data suggest that olanzapine is more efficacious than a number of other antipsychotic drugs in the longer term, but its efficacy must be weighed against its side effect profile.
6. Sensory evaluation of the bitterness of asenapine using D-sorbitol pretreatment: single-blind, placebo-controlled, crossover trial.
BMC Psychiatry 2023;23:1. PMID: 36918838 , PubMed Central, doi: 10.1186/s12888-023-04664-5, Cited by. Cite
Conclusion: Ethics approval was obtained from the Nagoya University Clinical Research Review Board.
7. Boosting the In Vivo Transdermal Bioavailability of Asenapine Maleate Using Novel Lavender Oil-Based Lipid Nanocapsules for Management of Schizophrenia.
Pharmaceutics 2023;15:2. PMID: 36839811 , PubMed Central, doi: 10.3390/pharmaceutics15020490, Cited by. Cite
Conclusion: They increased the bioavailability of ASP by up to 52% and provided sustained release for three days. The pharmacokinetic profile of the LO-LNCs was compared to ASP-loaded invasomes (discussed in a previous study) to emphasize LNCs' transdermal delivery behavior.
8. Comparison of antipsychotic dose equivalents for acute bipolar mania and schizophrenia.
BMJ Ment Health 2023;26:1. PMID: 36789916 , PubMed Central, doi: 10.1136/bmjment-2022-300546, Cited by. Cite
Conclusion: een considered first-line treatment for acute mania, warranting specific dose equivalence for scientific and clinical purposes.
9. Efficacy of Asenapine in Drug-resistant Psychotic Patients with Dopamine Supersensitivity Psychosis: Two Cases.
Clin Psychopharmacol Neurosci 2023;21:1. PMID: 36700326 , PubMed Central, doi: 10.9758/cpn.2023.21.1.197, Cited by. Cite
Conclusion: Asenapine binds to a broad range of dopamine receptors and serotonin receptors, and it is thus distinct from other atypical antipsychotics. The unique profile of asenapine may contribute to the control of severe DSP symptoms in individuals with schizophrenia.
10. The Atypical Antipsychotic Lurasidone Affects Brain but Not Liver Cytochrome P450 2D (CYP2D) Activity. A Comparison with Other Novel Neuroleptics and Significance for Drug Treatment of Schizophrenia.
Cells 2022;11:21. PMID: 36359909 , PubMed Central, doi: 10.3390/cells11213513, Cited by. Cite
Conclusion: In conclusion, lurasidone regulates brain (but not liver) CYP2D activity/protein level in a region-dependent manner, which is similar to that of other atypical neuroleptics (iloperidone and asenapine) as concerns the frontal cortex (down-regulation) and nigrostriatal pathway (up-regulation) and may be of pharmacological significance. However, further molecular studies with selective receptor agonists are necessary to find out which individual monoaminergic receptors/signaling pathways are involved in the regulation of the rat CYP2D4 and human CYP2D6 enzyme in particular brain structures.
11. Efficacy of HP-3070, an Asenapine Transdermal System, on Symptoms of Hostility in Adults With Schizophrenia: A Post Hoc Analysis of a 6-Week Phase 3 Study.
J Clin Psychiatry 2022;83:4. PMID: 35687858 , doi: 10.4088/JCP.21m14355, Cited by. Cite
Conclusion: /i> In this post hoc analysis, HP-3070 was superior to placebo in reducing schizophrenia-associated hostility, even after adjusting for covariates, suggesting these effects are at least partially independent of general antipsychotic effects or effects on sedation or akathisia. These findings suggest HP-3070 has a specific antihostility effect in patients with schizophrenia. Clinical Trials Registration: ClinicalTrials.gov identifier: NCT02876900; EudraCT number: 2015-005134-21.
12. Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants.
World Psychiatry 2022;21:2. PMID: 35524620 , PubMed Central, doi: 10.1002/wps.20972, Cited by. Cite
Conclusion: This finding is of particular relevance for low- and middle-income countries and constrained-resource settings, where few medications may be selected. Results from this network meta-analysis can inform clinical guidelines and national and international drug regulation policies.
13. Comparative Efficacy and Tolerability of Antipsychotics for Juvenile Psychotic Disorders: A Systematic Review and Network Meta-Analysis.
J Clin Psychopharmacol 2022 Mar-Apr 01;42:2. PMID: 35020712 , doi: 10.1097/JCP.0000000000001506, Cited by. Cite
Conclusion: Some antipsychotics were effective and tolerated short term, but longer-term evidence was very limited. The overall paucity of trials and of adequate controls indicates that more well-designed randomized controlled trials are required for adequate assessment of antipsychotic drug treatment for juveniles.
14. Long-Acting Injectable Antipsychotic Treatment in Schizophrenia and Co-occurring Substance Use Disorders: A Systematic Review.
Front Psychiatry 2021;12:. PMID: 34975600 , PubMed Central, doi: 10.3389/fpsyt.2021.808002, Cited by. Cite
Conclusion: /b> LAI antipsychotics may be an efficacious intervention option for the treatment of SCZ-SUDs. However, varying methodological rigor, generally small sample sizes and heterogeneity of samples, settings, substances of abuse, tested LAIs and comparators, as well as psychosocial cotreatments and level of reported detail across studies requires that these findings be considered preliminary and interpreted with caution. Further research is required to better understand the effects of LAIs among individuals with SCZ-SUDs.
15. Treatment Continuation of Asenapine or Olanzapine in Japanese Schizophrenia Patients: A Propensity Score Matched Study.
Neuropsychiatr Dis Treat 2021;17:. PMID: 34934318 , PubMed Central, doi: 10.2147/NDT.S343840, Cited by. Cite
Conclusion: The low continuation rate of asenapine in real-world data may be related to specific factors such as bitter taste and burden of the dosing method.
16. Development and Optimization of Asenapine Sublingual Film Using QbD Approach.
AAPS PharmSciTech 2021;22:7. PMID: 34608546 , doi: 10.1208/s12249-021-02132-5, Cited by. Cite
Conclusion: In vivo study indicates greater asenapine absorption (31.18 ± 5.01% of administered dose) within 5 min and was comparable with marketed formulation. In summary, the designing plan to develop asenapine formulation was successfully achieved with desired characteristics of the delivery tool for sublingual administration.
17. Enhancement of the Solubility of Asenapine Maleate Through the Preparation of Co-Crystals.
Curr Drug Deliv 2022;19:7. PMID: 34353260 , doi: 10.2174/1567201818666210805154345, Cited by. Cite
Conclusion: Co-crystals with improved solubility/dissolution rate of asenapine maleate were prepared successfully and were expected to enhance the bioavailability of the drug.
18. The Influence of Long-Term Treatment with Asenapine on Liver Cytochrome P450 Expression and Activity in the Rat. The Involvement of Different Mechanisms.
Pharmaceuticals (Basel) 2021;14:7. PMID: 34209648 , PubMed Central, doi: 10.3390/ph14070629, Cited by. Cite
Conclusion: Thus, chronic asenapine treatment may slow the metabolism of CYP1A, CYP2B, CYP2C11 and CYP3A substrates (steroids and drugs). Since asenapine is metabolized by CYP1A and CYP3A, the neuroleptic may inhibit its own metabolism, therefore, the plasma concentration of asenapine in patients after prolonged treatment may be higher than expected based on a single dose.
19. Efficacy and safety of antipsychotic treatments for schizophrenia: A systematic review and network meta-analysis of randomized trials in Japan.
J Psychiatr Res 2021;138:. PMID: 33964682 , doi: 10.1016/j.jpsychires.2021.04.032, Cited by. Cite
Conclusion: those of previous network meta-analysis involving various races and ethnicities.
20. Treatment-resistant schizophrenia characterised by dopamine supersensitivity psychosis and efficacy of asenapine.
BMJ Case Rep 2021;14:4. PMID: 33849886 , PubMed Central, doi: 10.1136/bcr-2021-242495, Cited by. Cite
Conclusion: The patient was then started on second-generation antipsychotic asenapine while other antipsychotics were tapered off, resulting in improvement of these symptoms. Retrospectively, we presumed that the high-dose antipsychotic polypharmacy caused DSP, which was effectively treated by the potent 5-HT2A receptor antagonism of asenapine.
21. Head-to-Head Comparison of Sedation and Somnolence Among 37 Antipsychotics in Schizophrenia, Bipolar Disorder, Major Depression, Autism Spectrum Disorders, Delirium, and Repurposed in COVID-19, Infectious Diseases, and Oncology From the FAERS, 2004-2020.
Front Pharmacol 2021;12:. PMID: 33841149 , PubMed Central, doi: 10.3389/fphar.2021.621691, Cited by. Cite
Conclusion: /b> We conducted a head-to-head comparison of thirty-seven antipsychotics and ranked the compounds based on the association of sedation and somnolence from ADR data collected throughout 16 years from the FAERS. The results are informative and with recent interests in repurposing phenothiazine antipsychotics in infectious disease and oncology provides an informative assessment of the compounds during repurposing and in psychopharmacology.
22. Pharmacokinetic Profile of the Asenapine Transdermal System (HP-3070).
J Clin Psychopharmacol 2021 May-Jun 01;41:3. PMID: 33734167 , PubMed Central, doi: 10.1097/JCP.0000000000001383, Cited by. Cite
Conclusion: Based on these PK metrics, HP-3070 steadily delivers asenapine with lower peaks and troughs than sublingual administration of asenapine.
23. Continuation rate for asenapine and brexpiprazole treatment in patients with schizophrenia.
Brain Behav 2021;11:5. PMID: 33713580 , PubMed Central, doi: 10.1002/brb3.2109, Cited by. Cite
Conclusion: brexpiprazole increases as the age of the patient increases, as disease severity decreases, and if the patient first uses the drug as an outpatient. Shorter disease duration and longer drug administration may lead to improved clinical efficacy. These results suggest that brexpiprazole is an effective treatment option for maintenance therapy of schizophrenia.
24. Effects of Antipsychotics on Arrhythmogenic Parameters in Schizophrenia Patients: Beyond Corrected QT Interval.
Neuropsychiatr Dis Treat 2021;17:. PMID: 33542628 , PubMed Central, doi: 10.2147/NDT.S287042, Cited by. Cite
Conclusion: According to our results, the prediction of the risk of sudden cardiac death by each index was inconsistent. We should evaluate the predictive factor of ventricular arrhythmia according to various electrocardiogram indexes because QTc alone could not identify the risk of sudden cardiac death.
25. Divergence of dose-response with asenapine: a cluster analysis of randomized, double-blind, and placebo control study.
CNS Spectr 2022;27:3. PMID: 33461636 , doi: 10.1017/S1092852921000043, Cited by. Cite
Conclusion: asenapine 10 and 20 mg/day differed between the 3 clusters of patients. This suggests that background information regarding baseline psychiatric symptoms may affect the therapeutic response in patients with schizophrenia.
26. Efficacy Comparison for a Schizophrenia and a Dysuria Drug Among East Asian Populations: A Retrospective Analysis Using Multi-regional Clinical Trial Data.
Ther Innov Regul Sci 2021;55:3. PMID: 33393013 , doi: 10.1007/s43441-020-00246-9, Cited by. Cite
Conclusion: regional efficacy differences were found for the two drugs among the three regions. This finding supported the possible applicability of the region pooling strategy for MRCTs in East Asia, emphasizing the benefits of exploring ethnic difference/influencing factors at an early stage to design further confirmatory studies. However, further evidence for various drugs should be accumulated.
27. Efficacy and Safety of HP-3070, an Asenapine Transdermal System, in Patients With Schizophrenia: A Phase 3, Randomized, Placebo-Controlled Study.
J Clin Psychiatry 2020;82:1. PMID: 33326711 , doi: 10.4088/JCP.20m13602, Cited by. Cite
Conclusion: 8 mg/24 h doses were efficacious and well tolerated. As the first transdermal antipsychotic patch available in the US, HP-3070 offers a novel treatment option for people with schizophrenia.
28. A Randomized Controlled Trial to Compare the Efficacy, Safety and Tolerability of Asenapine versus Olanzapine in Management of Schizophrenia.
Clin Psychopharmacol Neurosci 2020;18:4. PMID: 33124591 , PubMed Central, doi: 10.9758/cpn.2020.18.4.587, Cited by. Cite
Conclusion: Newer atypical antipsychotic asenapine is more effective than standard olanzapine in reducing the symptoms of schizophrenia in this study and further larger studies are to be done.
29. Updating the Comparative Evidence on Second-Generation Antipsychotic Use With Schizophrenia.
Psychiatr Res Clin Pract 2020;2:2. PMID: 36101867 , PubMed Central, doi: 10.1176/appi.prcp.20200004, Cited by. Cite
Conclusion: ost comparative evidence favored older SGAs, with clozapine, olanzapine, and risperidone superior on more outcomes than other SGAs. Older SGAs had similar benefits as haloperidol but with fewer adverse events.
30. Long-term sustained release Poly(lactic-co-glycolic acid) microspheres of asenapine maleate with improved bioavailability for chronic neuropsychiatric diseases.
Drug Deliv 2020;27:1. PMID: 32885707 , PubMed Central, doi: 10.1080/10717544.2020.1815896, Cited by. Cite
Conclusion: The results suggest that ASM-PLGA microspheres prepared by the microfluidic method provide an efficient strategy to enhance the drug exposure of ASM as the treatment of chronic neuropsychiatric diseases. It is also evident that this microfluidic strategy has the potential to construct with other drugs, establishing long-acting formulations.
31. The Effects of Antipsychotics on the Synaptic Plasticity Gene Homer1a Depend on a Combination of Their Receptor Profile, Dose, Duration of Treatment, and Brain Regions Targeted.
Int J Mol Sci 2020;21:15. PMID: 32756473 , PubMed Central, doi: 10.3390/ijms21155555, Cited by. Cite
Conclusion: Biological effects of antipsychotics on Homer1a varied strongly depending on the combination of their receptor profile, dose, duration of administration, and throughout the different brain regions. These molecular data may have translational valence and may reflect behavioral sensitization/tolerance phenomena observed with prolonged antipsychotics.
32. The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey.
Ann Gen Psychiatry 2020;19:. PMID: 32684942 , PubMed Central, doi: 10.1186/s12991-020-00292-5, Cited by. Cite
Conclusion: Stable patients with schizophrenia taking second-generation antipsychotics live with many side effects, including activating and sedating side effects, sexual side effects, and weight gain. Presence of these side effects is associated with substantial impacts across all aspects of daily functioning and lower quality of life and satisfaction.
33. One-pot reaction for determination of Asenapine maleate through facile complex formation with xanthine based dye: Application to content uniformity test.
Spectrochim Acta A Mol Biomol Spectrosc 2020;239:. PMID: 32450539 , doi: 10.1016/j.saa.2020.118474, Cited by. Cite
Conclusion: The formation constant of the reaction was 3.93 × 104 while its Gibb's free energy was -2.6 × 104 J mol-1. Finally, the methods were applied for the analysis of pharmaceutical tablets and for evaluation of their content uniformity.
34. Surface engineered nanoliposomal platform for selective lymphatic uptake of asenapine maleate: In vitro and in vivo studies.
Mater Sci Eng C Mater Biol Appl 2020;109:. PMID: 32228915 , doi: 10.1016/j.msec.2019.110620, Cited by. Cite
Conclusion: Imaging studies showed that RGD peptide conjugated liposomes were successful in targeting the Peyer's patches, both in vivo and ex vivo. The study successfully demonstrated the improved pharmacokinetics and efficacy profile of ASPM by using a ligand conjugated targeted liposomal system.
35. Early improvements of individual symptoms as a predictor of treatment response to asenapine in patients with schizophrenia.
Neuropsychopharmacol Rep 2020;40:2. PMID: 32180369 , PubMed Central, doi: 10.1002/npr2.12103, Cited by. Cite
Conclusion: ive symptoms, poor attention and impulse control, and lack of insight, in particular predicted subsequent treatment response in patients with schizophrenia during treatment with asenapine as accurately as prediction based on overall symptom severity.
36. Risk of Mortality Associated With Atypical Antipsychotic use: A National Cohort Study of Older Adults With Depression and Parkinson's Disease.
Am J Geriatr Psychiatry 2020;28:10. PMID: 32147383 , doi: 10.1016/j.jagp.2020.01.193, Cited by. Cite
Conclusion: ssociated with a higher risk of all-cause-mortality in older patients with PD which is mainly mediated by pneumonia. Therefore, inappropriate AAP use should be avoided to improve quality of care in PD.
37. Blonanserin patch vs. Other Antipsychotics for Acute Schizophrenia: A Systematic Review of Double-blind, Randomized, Placebo-controlled, Phase 3 Trials in Japan.
Pharmacopsychiatry 2020;53:3. PMID: 32000271 , doi: 10.1055/a-1096-1266, Cited by. Cite
Conclusion: Pooled data for patients receiving BLO-P 40 and 80 mg/day (BLO-P40+80) were compared with pooled data for patients receiving asenapine 10 and 20 mg/day (ASE10+20) and data for those receiving brexpiprazole 2 mg/day (BRE2) and paliperidone extended-release 6 mg/day (PAL-ER6).
38. Dose-Response Meta-Analysis of Antipsychotic Drugs for Acute Schizophrenia.
Am J Psychiatry 2020;177:4. PMID: 31838873 , doi: 10.1176/appi.ajp.2019.19010034, Cited by. Cite
Conclusion: atients with acute exacerbations, doses higher than the identified 95% effective doses may on average not provide more efficacy. For some drugs, higher than currently licensed doses might be tested in further trials, because their dose-response curves did not plateau.
Impact/quality: Governmental/foundation support *
39. Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis.
Eur Child Adolesc Psychiatry 2020;29:9. PMID: 31758359 , PubMed Central, doi: 10.1007/s00787-019-01425-2, Cited by. Cite
Conclusion: Rates of EPS and akathisia were similar for lurasidone and other atypical antipsychotics. In this network meta-analysis of atypical antipsychotics in adolescent schizophrenia, lurasidone was associated with similar efficacy, less weight gain, and lower risk of all-cause discontinuation compared to other oral atypical antipsychotics.
40. Efficacy of Asenapine in Schizophrenia Resistant to Clozapine Combined with Electroconvulsive Therapy: A Case Report.
Clin Psychopharmacol Neurosci 2019;17:4. PMID: 31671497 , PubMed Central, doi: 10.9758/cpn.2019.17.4.559, Cited by. Cite
Conclusion: Asenapine, considered a serotonin spectrum dopamine modulator, is a new atypical antipsychotic with unique pharmacological features that is used not only for schizophrenia, but also for bipolar disorder. The unique features of asenapine may be effective for some treatment-refractory schizophrenic patients.
41. Lithium Neurotoxicity Due to Second-Generation Antipsychotics Combined With Lithium: A Systematic Review.
Prim Care Companion CNS Disord 2019;21:3. PMID: 31237432 , doi: 10.4088/PCC.17r02225, Cited by. Cite
Conclusion: LN, both reversible and irreversible, due to SGAs combined with lithium presents with certain causative factors and a clinical profile. Early detection and prompt management will help prevent LN.
42. Medication-Induced Akathisia with Newly Approved Antipsychotics in Patients with a Severe Mental Illness: A Systematic Review and Meta-Analysis.
CNS Drugs 2019;33:6. PMID: 31065941 , doi: 10.1007/s40263-019-00625-3, Cited by. Cite
Conclusion: e akathisia risk more than two-fold when compared with patients receiving placebo. Although distinctions between the different NAPs were not clear in placebo-controlled trials, the results of our meta-analyses and systematic review generally indicate that these differences more than likely reflect real differences, with iloperidone showing the most and cariprazine showing the least benign akathisia profile. Moreover, due to patient characteristics and methodological issues, incidence rates of akathisia with NAPs found in this meta-analysis may even be an underestimation of true incidence rates.
43. Asymmetric total synthesis of (+)-asenapine.
Org Biomol Chem 2019;17:12. PMID: 30840011 , doi: 10.1039/c9ob00178f, Cited by. Cite
Conclusion: Asymmetric total synthesis of (+)-asenapine, an atypical antipsychotic drug, used for treating schizophrenia and acute mania associated with bipolar disorder, is reported. The key steps are the organocatalytic Michael addition of aldehydes to trans-nitroalkenes and subsequent reductive cyclization.
44. Enhanced intestinal absorption of asenapine maleate by fabricating solid lipid nanoparticles using TPGS: elucidation of transport mechanism, permeability across Caco-2 cell line and in vivo pharmacokinetic studies.
Artif Cells Nanomed Biotechnol 2019;47:1. PMID: 30669881 , doi: 10.1080/21691401.2018.1546186, Cited by. Cite
Conclusion: The pharmacokinetic results in rats showed 50.19-fold improvement in BA of AM after fabrication of SLNs. Collectively, all these findings demonstrated effectiveness of SLNs to improve therapeutic efficacy of AM in the treatment of schizophrenia.
45. Asenapine pharmacokinetics and tolerability in a pediatric population.
Drug Des Devel Ther 2018;12:. PMID: 30214156 , PubMed Central, doi: 10.2147/DDDT.S171475, Cited by. Cite
Conclusion: Asenapine was generally safe and well tolerated in pediatric patients aged 10-17 years. PK and safety data were similar to that observed in the adult population. Intrinsic factors had no significant impact on asenapine exposure, indicating there is no need for dose adjustments in the pediatric population.
46. Movement Disorders Associated With Antipsychotic Medication in People With Schizophrenia: An Overview of Cochrane Reviews and Meta-Analysis.
Can J Psychiatry 2018;63:11. PMID: 29758999 , PubMed Central, doi: 10.1177/0706743718777392, Cited by. Cite
Conclusion: La variation des chiffres de la prévalence entre antipsychotiques a été observée pour les différents troubles du mouvement. Les différences des propriétés pharmacologiques comme la vitesse d'association de D2R et de l'antagonisme 5-HT2A pourraient contribuer à cette variation.
47. QTc Prolongation and Ventricular Trigemini with Asenapine: A Case Report.
Turk Psikiyatri Derg 2018;29:1. PMID: 29730876 , Cited by. Cite
Conclusion: These changes ceased following withdrawal of asenapine. In this case report, we discuss the importance of cardiac monitoring when switching antipsychotics, even to those that are considered to have low cardiac risk.
48. Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
J Comp Eff Res 2018;7:7. PMID: 29694244 , doi: 10.2217/cer-2018-0010, Cited by. Cite
Conclusion: cost effective in the maintenance monotherapy treatment of BP-I in adults.
49. Budget impact analysis of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
J Comp Eff Res 2018;7:7. PMID: 29694243 , doi: 10.2217/cer-2018-0009, Cited by. Cite
Conclusion: al antipsychotics are predicted to increase, payers may wish to re-evaluate their use.
50. Reversal of olanzapine-induced weight gain in a patient with schizophrenia by switching to asenapine: a case report.
Neuropsychiatr Dis Treat 2017;13:. PMID: 29200857 , PubMed Central, doi: 10.2147/NDT.S148616, Cited by. Cite
Conclusion: Asenapine might be effective for treating patients with schizophrenia who experience olanzapine-induced weight gain.
Show evidence search details (access to earlier iterations If results displayed are too restrictive)
 
 
You found 50 or more articles.
Consider performing your search at Trip Database. Trip curates the articles it indexes so you may get a smaller number of more helpful documents.
Thursday, 28 Mar 2024 04:14:12 at SUMSearch
 
Questions: rbadgett@kumc.edu